eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

The poster titled “eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)” was presented by Kevin R. Webster, Ph.D., on December 5, 2015 at the 57th Annual 2015 American Society of Hematology (ASH) meeting in Orlando, FL.

Contact
Heidi Chokeir, Ph.D.
619-849-5377

heidi@canalecomm.com